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Mutation of the mtATP6 gene, which encodes an essential subunit of the F0F1-ATP synthase 
(Complex V) in mitochondria, is known to cause a group of related encephalomyopathies.  The 
ATP synthase acts as a hydrogen ion transporter that couples ion dissipation with ATP 
production.  Diseases including NARP (neuropathy ataxia and retinitis pigmentosa) and MILS 
(maternally inherited Leigh’s syndrome) are caused by missense mutations in the ATP6 gene.  
Drosophila melanogaster, the common fruit fly, has a mitochondrial ATP6 missense mutation 
that models NARP/MILS diseases.  Our aim is to develop a transgenic strategy where allotopic 
expression of a mitochondrial-targeted ATP6 mRNA may serve as a potential gene therapy for 
these devastating mitochondrial diseases.  Mitochondria in metazoans are known to import 
nuclear encoded 5SrRNAs, which are thought to be essential for mitochondrial protein synthesis.  
We utilized a cluster of 100 individual 5S rRNA genes found at 56F region of the right arm of 
chromosome 2 in Drosophila melanogaster.  Sequence comparisons revealed 17 groups of 
genomic variants and 14 processed rRNA counterparts.  Identifying which, if any, of the known 
5S rRNAs are competent for mitochondrial import was integral to our proposed gene therapy 
approach.  A protocol was developed that utilizes gradient and percoll centrifugation steps to 
isolate highly purified mitochondria that lack detectable cytosolic contamination.  RT-PCR and 
cloning were used to determine which 5S rRNAs were expressed and localized to the 
mitochondria.  The cytoplasmic and mitochondrial derived clones and gDNA control clones 
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support the assertion that, at least under normal in vivo conditions, ~ 60 % of the identified 5S 
rRNA genes are not expressed and are likely pseudogenes.  One variant, 5S rRNA III, is 
predominantly expressed and localized to the mitochondria.  Also, 8 novel and 3 possible 5S 
rRNA gene isoforms not currently categorized in sequence databases have been discovered.  
Clones capable of expressing chimeric rRNA::mRNAs in cells and in vivo were generated.  These 
constructs could later be used to assess the ability of 5S rRNA to direct mitochondrial import of 
“passenger” mRNAs. 
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Nomenclature used: mtATP6 gene, ATP Synthase, sesB1/ANT1 (stress-sensitive B) / 
(Adenine Nucleotide Transporter 1), encephalomyopathies, NARP (neuropathy ataxia and 
retinitis pigmentosa), MILS (maternally inherited Leigh’s syndrome), missense mutations, 
progressive neuromuscular impairment, myodegeneration, allotopic expression, transgene, gene 
therapy  
1.0  INTRODUCTION 
Mitochondrial diseases are a collection of relatively common genetic disorders affecting 10-15 
people per 100,000 individuals (DiMauro and Schon, 2003).  This impairment of respiration or 
the electron transport chain has been linked to multiple neurodegenerative diseases including: 
Huntington’s, Alzheimer’s, and Parkinson’s diseases, ALS, and mitochondrial 
encephalomyopathies (Orth and Schapira, 2001).  Mutations, directly affecting mitochondrial 
genes or altering nuclear genes that encode proteins imported into the mitochondria, have been 
found to cause a similar group of encephalomyopathies.  Along with prominent neurological and 
muscular dysfunction, patients experience marked complications in other organs or organ 
systems including hepatic, digestive, cardiac, and endocrine (Schapira and Cock, 1999; DiMauro 
and Schon, 2003). 
ATP6 is one of 13 protein coding genes and 24 RNA coding genes (2 rRNAs and 22 
tRNAs) in the mitochondrial genome of Drosophila (Lewis et al., 1995) and humans (Entelis et 
al, 2002).   The ATP6 gene encodes an essential subunit of the F0F1-ATP synthase (Complex V).  
Under normal conditions Complex V acts as hydrogen ion transporter that couples hydrogen ion 
dissipation down its electrochemical gradient to rotary ATP production from ADP and inorganic 
phosphate (Mitchell and Moyle, 1967; Boyer 1997; Stock et al., 2000).  Mutations affecting 
ATP6 cause a group of related encephalomyopathies.  Diseases such as NARP (neuropathy 
ataxia and retinitis pigmentosa) and MILS (maternally inherited Leigh’s syndrome) are caused 
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by missense mutations in the ATP6 gene with hypotheses that oxidative damage and/or 
bioenergetic impairment due to respiratory chain dysfunction lead to the pathogenesis found in 
these mitochondrial encephalomyopathies (Orth and Schapira, 2001). 
  In 2006, Celotto et al, discovered the ATP61 mitochondrial mutation as a maternally 
inherited enhancer in their sesB1/ (ANT1) stock.  sesB1 animals are stress-sensitive and are 
paralyzed by mechanical stress.  The sesB1 strain is adult viable and previous studies in the 
laboratory have shown that conditional paralysis mutants are enriched for those with 
neurodegeneration (Palladino et al, 2002).  A maternally inherited enhancer of sesB1 was 
discovered, genetically isolated from the sesB1 mutation and named MATBS (maternal isolate, 
bang sensitive; Celotto et al, 2006).  In studying the mitochondria genome of MATBS one 
missense mutation was revealed: G-A transition leading to a glycine to glutamate codon change 
at 116 of the ATP6 gene.  Further research showed that the glycine residue at 116 was invariant 
among many species.  This was a key finding, the first pathogenic mitochondrial DNA mutation 
to be isolated in a genetic model system (Celotto et al, 2006).  ATP61 results in neural 
dysfunction, progressive myodegeneration, locomotor impairment, and decreased lifespan. 
Furthermore, ATP61 enhances many phenotypes of sesB1 including locomotor impairment and 
longevity defects.  For example, reduced median lifespan compared to wild type flies in sesB1, 
ATP61, and double mutant were 31%, 67%, and 76% respectively (Celotto et al, 2006).   
 Encephalomyopathies are a devastating group of disorders that can affect humans at any 
stage and age of life.  According to DiMauro and Schon (2003), they are caused by over 150 
mutations from point or missense mutations to deletions of portions of the mitochondrial 
genome.  The main factor determining when and to what degree a person will get an 
encephalomyopathy is the percent heteroplasmy of the mutation.  In humans, for example, the 
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ATP6 missense mutation L156R is aphenotypic under 70% mutant heteroplasmy (30% normal).  
However, mutant heteroplasmy of 70-90% typically results in the adult onset NARP, whereas, 
greater than 90% mutant heteroplasmy results in the more severe childhood onset MILS.  The 
ATP61 mutant in Drosophila was characterized by clonal analysis and found to have a high 
mutant heteroplasmy (~ 98 ± 2%) suggesting this mutant may model the more severe MILS 
encephalomyopathy (Celotto et al, 2006).  Like many mitochondrial diseases efficacious 
treatments are not currently available. 
For my thesis research, we aimed to develop a transgenic strategy that utilizes allotopic 
expression of RNA as a potential gene therapy for the ATP6 loss-of-function mutation.  Several 
lines of evidence suggest mitochondria have an RNA import pathway.  Since ATP6 is a 
mitochondrial-encoded gene, we propose a carrier RNA molecule will be necessary to transport 
the wild-type ATP6 mRNA from a nuclear source.  We hypothesized that the 5S rRNA might 
serve such a role since the mitochondria contain their own protein synthesis machinery and 
previous data suggested that 5S rRNAs are imported into mitochondria from the nucleus 
(Magalhaes et al, 1998; Entelis et al, 2001). 
Mitochondria, remnant of their symbiotic origin, have their own protein synthesis 
machinery and the mtDNA encodes the 12S rRNA and 16S rRNA but the 5S rRNA can be 
encoded in either the nucleus or mitochondria and there is controversy as to whether the 5S rRNA 
is a functional part of a mitochondrial ribosome (Entelis et al, 2001).   For example, the mtDNA 
of species such as plants, algae and some protozoans encode for the 5S rRNA gene and 5S rRNAs 
have been found in mitochondrial ribosomes of these species (Entelis et al, 2001).  In eukaryotes, 
including Drosophila, fungi, and mammals, the 5S genes are nuclear and some believe that 5S 
rRNAs are not incorporated into mitochondrial ribosomes of these species (Entelis et al, 2001).  
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Magalhaes et al, 1998 and Yoshionari et al, 1994 used synthetic and natural 5S rRNAs to show 
that 5S can enter into the mitochondria, but this does not address whether it is part of the 
mitochondrial ribosome.  These are two separate issues whether the 5S rRNA is a functional part 
of the mitochondrial ribosome and if the 5S rRNA can be imported from the nucleus into the 
mitochondria.  5S rRNA import into the mitochondria is of principle interest as a vehicle to target 
passenger mRNAs for a viable gene therapy approach. 
   Previous studies in Drosophila estimated there to be between 100-165 5SrRNA genes 
found in a single tandem array at region 56F on the right arm of chromosome two (Spradling and 
Rubin, 1981).  Early 5S rRNA transcripts are 135 nucleosides (NS) with 3’ post-transcriptional 
cleavage of the last 15 nucleosides to produce a mature 120 NS rRNA.  Each gene in the array 
encodes a 135 bp pre-rRNA, a poly-T region thought to direct RNAPol III where to terminate 
transcription, and a “spacer” region of approximately 238bp (Spradling and Rubin, 1981).   
Many researchers disagree whether a negatively charged RNA molecule can cross 
through hydrophobic membranes with an electrical potential to enter the mitochondria (Entelis et 
al, 2001). However, 5S rRNA has been shown to enter mammalian mitochondria even into the 
internal matrix using an assay with highly purified mitoplast preparations (Magalhaes et al, 
1998).  Natural and synthetic 5S rRNAs and other RNAs are known to be imported, including 
tRNAs (natural and synthetic) in eukaryotes and synthetic in mammalian cells (Magalhaes et al, 
1998; Entelis et al, 2001).  Nuclear encoded ribozymes, including RNase H, RNase P, and RNase 
MRP have also been found in the mitochondria of Humans (Entelis et al, 2001).  The combined 
ability of mitochondria from yeast to mammalian culture cells to import RNA provides evidence 
for a mitochondrial RNA import pathway.  
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The presence of an RNA import pathway suggests an avenue that could be exploited for 
gene therapy of mitochondrial-based diseases.  Mitochondria are polyploidy with an estimated 3-
30 genomes per mitochondria.  However, these organelles are the proverbial “power house” of 
the cell providing most of the energy the cell needs to carry on daily functions via the citric acid 
cycle and the electron transport chain, processes known to produce unstable free radicals and 
superoxides.  As a result mutation rates in the mitochondrial genome are much higher than in the 
nuclear genome.  When mutations compromise mitochondrial function one of several terrible 
diseases collectively referred to as mitochondrial encephalomyopathies results.  Unfortunately, 
these diseases lack a useful treatment and only symptomatic care is provided.  Gene therapy is 
effectively used for other diseases where no successful drug therapy is available, such as cystic 
fibrosis.  However, with current technology we are not able to manipulate the mitochondrial 
genome.  Allotopic RNA gene therapy would utilize existing gene therapy mechanisms of 
administration that utilize viruses to integrate a gene into the nuclear DNA.  This gene could 
encode a fusion rRNA::mRNA where the rRNA is a carrier that would be recognized by the RNA 
import pathway and the mRNA is a WT gene referred to a passenger (Figure 1).  Should the 
structural requirements of RNA import be identified this would open up the possibility for 
development of treatments for any mitochondrial encephalomyopathy.  
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2.0  IDENTIFICATION OF 5S RNAS EXPRESSED AND LOCALIZED TO THE 
MITOCHONDRIA  
To reiterate the most important aspect of my thesis research, we aimed to develop a 
transgenic strategy that utilized allotopic expression of RNA as a potential gene therapy for the 
ATP6 loss-of-function mutation.  Since ATP6 is a mitochondrial-encoded gene, we hypothesized 
that a small RNA molecule would be a sufficient carrier to transport the wild-type ATP6 mRNA 
from a nuclear source.  We propose that 5S rRNA might serve this role since the mitochondria 
contain their own protein synthesis machinery and previous data suggested that 5S rRNAs are 
imported from the nucleus (Yoshionari et al, 1994; Magalhaes et al, 1998; Entelis et al, 2002). 
However, we first had to characterize all of the known and annotated 5S rRNAs because 
there was very little evidence for a specific sequence or sequences found imported into 
mitochondria of flies or humans.   Benhamou and Jordan 1975, proposed a sequence for the most 
transcribed cytosolic 5S rRNA that we latter named variant III.  They further suggested that many 
of the other 5S genes were likely pseudogenes, DNA sequences that resemble functional genes 
but do not express any RNA or protein.  This information was a helpful start but for our project 
we needed specific 5S rRNAs that had entered the mitochondria, which required us to develop 
mitochondrial purification protocols and an assay for 5S rRNA expression.  Only these individual 
5S rRNAs that have entered the mitochondria would be the best vehicle to target passenger 
mRNAs for a feasible gene therapy approach. 
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2.1 MATERIALS AND METHODS 
5S rRNA Configurations. After searching for individual Drosophila melanogaster 5S rRNA 
sequences within NCBI Genome, D.m.5SJ01122, D.m.5SX87880, and D.m.5SM25016 were 
found (Figure 2).  BLAST searches with any one of these sequences sent us to the 56F region of 
Drosophila melanogaster chromosome 2 and to the 100 individual annotated genomic 5S rDNA 
sequences in Flybase (http://flybase.bio.indiana.edu).  DNASTAR software (Lasergene) was 
used to analyze the 100 sequences by homology into 17 genomic variants (Figure 3).  The 
predicted secondary structures of the 14 (120 NS) 5S rRNAs were made utilizing mfold 
(http://www.bioinfo.rpi.edu/applications/mfold).  5S rRNA III with 48 isoforms is shown as a 
representative (Figure 4).   
         Drosophila stocks and culture.  Standard cornmeal molasses fly media was used.  Canton 
S (CS) wild type stocks were mated to expand colonies in glass jars at room temperature.   
Isolation of Pure Mitochondria and Cytoplasm.  All steps were performed on ice or at 
4oC; centrifugation was with a Sorvall SS-34 rotor in a Sorvall RC6 Plus Centrifuge 
(Thermoelectron corp.).  All instruments and centrifuge tubes were pre-cleaned with RNase 
Displace a DNA-RNase remover (Fisher, #04-355-138), solutions were filter sterilized, and filter 
tips were used.  Approximately 2.0 g adult Drosophila CS flies were placed in 10 ml cold Buffer 
A [250 mM sucrose (Fisher, 55-3), 1 mM EDTA (Fisher, BP120-500), 50 mM Tris-HCl pH 7.4 
(Fisher, BP152-5)] with 1 mM DTT and 1:100 Protease Inhibitor cocktail (Roche) added before 
use.  The flies were homogenized 30 times with each pestle of Kontes Glass Dounce 
Homogenizer (OD = 27.22 mm) pestle A and B 21.38 mm and 21.44 mm, respectively.  The 
mixture was centrifuged at 1000xg for 10 min at 4oC.  The supernatant was carefully poured into 
a new 50 ml tube and centrifuged at 10,000xg for 15 min.  The supernatant was carefully poured 
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into a new 50 ml tube and is now called the crude-cytoplasm.  The second pellet (crude 
mitochondria) was resuspended, washed and centrifuged in 30 ml Buffer A at 10,000xg 3 times 
10 min each.  The crude-cytoplasm was spun 15 min at 60,000xg to pellet any broken 
mitochondria.  The supernatant (~7 ml) was now mitochondria-free-cytoplasm and was carefully 
poured into a new 50 ml tube, labeled, and kept on ice.  The mitochondrial pellet was 
resuspended in 1 ml Buffer B [250 mM sucrose, 1 mM EGTA (Calbiochem, #324626), 10 mM 
Tris-HCl pH 7.4] and carefully laid on top of a continuous percoll gradient of [2.2 ml (2.5 M 
sucrose), 6.65 ml (100% percoll (MP Biomedical, #19536)), 12.25 ml (10 mM Tris-HCl pH 7.4), 
42 μl (0.5 M EDTA)].  The gradient was centrifuged at 60,000xg for 45 min and the 
mitochondrial layer was the thin red band 2/3 of the way down the tube right above the dense 
clear percoll layer.  The mitochondria were red in this procedure because the CS flies have red 
eyes and the red eye pigments contaminate all aqueous layers.  To remove any contaminating 
percoll, the mitochondria were resuspended, washed and centrifuged in 30 ml Buffer B 
(10,000xg, 10 min) 3 times.  After the last wash the purified mitochondria were kept on ice until 
RNA extraction (Mitochondrial Protocol modified from Gasnier et al, 1993) (Figure 5).  
LiCl/Urea RNA extraction from Mitochondria and Cytoplasm. Ten ml of 3 M LiCl  
(Fisher, L120-500)/6M Urea (Fisher, U15-500) stored at -30oC was added to each sample and 
homogenized (30X pestle A and B).  The samples were placed at -30oC overnight to precipitate 
RNA. The samples were centrifuged at 10,000xg for 10 min, a pellet appeared and the 
supernatant was carefully decanted.  The pellet was resuspended in 1/10 the starting volume 1X 
TE/0.01%SDS (1ml if started with 10 ml LiCl/Urea).  Two phenol (pH 4.2 ± .2) (Fisher, 
BP1751-400) /chloroform (EMD, CX105514) extractions were performed: equal amounts were 
added, mixed well, and spun 5 min at 10,000xg.  After the second extraction, the aqueous (top) 
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layer was removed to a new 1.5 ml eppendorf tube (Figure 6).   
Ethanol precipitation of RNA.  The RNA was precipitated from a 1 ml extraction with 
1/40th the volume (25 μl) 4 M NaCl (Fisher, 5671-3) and 2.5 times the volume (2.5 ml) ethanol 
(Pharmco, #11ACS200).  The precipitated RNA was stored in this form at -80oC.   The RNA was 
centrifuged at 10,000xg for 10 min and the pellet resuspend in 50 μl DNA/RNase free water 
(Acros, 327390010).  One μl of RNase inhibitor (Invitrogen, #155-18-012) was added.  The 
RNA was DNase treated (2 μl of DNase at 4.5 μg/μl for 1 hr at 37oC) to remove any DNA 
contamination.  As before, the RNA was Phenol/Chloroform extracted, precipitated and a 
spectrophotometer was used to quantify the amount of RNA.  One μl of RNase inhibitor was 
added and the amount of RNA was adjusted with DNA/RNase free water such that the 
concentration was 5 μg/μl (Figure 6). 
Reverse-Transcriptase-PCR.  A 20 μl final volume reaction consisted of: 2 μl (10 mM 
dNTP), 2 μl (2 μM RT Primer), 2 μl (100 mM DTT), 4 μl (5X Buffer), 1 μl (RNase inhibitor), 
1μl (5 μg RNA), 6 μl  (DNA/RNase free water), and 2 μl RT ssIII (Invitrogen MMLVRT).  
Minus RT reactions were performed with 2 μl of H2O instead of the ssIII.  The reaction tubes, 
with the proper controls, were incubated at 45 oC for 1.5 hr then the temperature was increased to 
55 oC for 1.5 hr in a Thermal Cycler (MJ Research PTC-200 Peltier Thermal Cycler) (Figure 6). 
 Hot Start-Touchdown PCR.  This following protocol was used for all rRNAs (5S, 28S, 
16S) and gDNA control reactions.  Starter 50 μl PCR reactions consisted of 10 μl (5X Buffer {at 
1X contains 1.5 mM MgCl2}), 4 μl (10 mM dNTPs (Fisher, BP, 2564-4)), 4 μl (2 μM Forward 
Primer), 4 μl (2 μM Reverse Primer), 4.5 μl (50 mM MgCl2), 3 μl (cDNA), 20 μl (DNA/RNase 
free water), and 0.5 μl (Go-Taq Polymerase, Promega).  PCR conditions were: 1) 940C → 2 min, 
2) 940C → 30 sec, 3) 560C → 30 sec, 4) 720C → 30 sec, 5) Repeat steps 2-4 (10 times), 6) 940C 
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→ 30 sec, 7) 530C → 30 sec, 8) 720C → 30 sec, 9) Repeat steps 6-8 (10 times), 10) 940C → 30 
sec, 11) 500C → 30 sec, 12) 720C → 30 sec, 13) Repeat steps 10-12 (20 times), 14) 720C → 6 
min, 15) 40C → hold.  Approximately 1.5 min into step (1) the program was paused and 0.5 μl of 
Taq was added to each tube.  A 2.5% agarose gel [6 g Quick Dissolve Agarose (Gene Pure LE, 
#E-3199-500), 1.5 g Agarose Low Melt (Fisher, BP-1360-100), 300 ml 1X TBE, 15 μl 1% 
ethidium bromide] was electrophoresed to pre-stain PCR products and the results were observed 
on a Bio Doc-ItTM Imaging System.  PCR conditions were confirmed using gDNA and 5S, 28S, 
and 16S primers to insure one condition per set of reactions (Figure 7) (PCR conditions modified 
from Nishimura et al, 1982)  
PCR-Primers.  Three primers were synthesized to PCR amplify the 14 different ~120 bp 
5S rRNA products known to exist in the wild type fly: 5S F, 5S R Deg, and 5S R 3371 (IDT, 
Inc).   Controls to amplify the 28SrRNA (28S F and 28S R) and 16SrRNA (16S F and 16S R) 
were also synthesized (IDT, Inc.) (Table 1). 
Reverse Transcriptase-PCR Primers.  The RT primer for the cytoplasmic control was 
28S RT; likewise the mitochondrial RT control was 16S RT.   The same 5S primers (5S R Deg) 
and (5S R 3371) used for regular PCR were used as RT primers (Table 1). 
Cloning.  The TOPO TA Cloning® Kit (Invitrogen, 45-0641) was used and contained the 
PCR 2.1 TOPO® Vector.  Vendor’s instructions were followed.  Briefly, in a 6 μl reaction [1 μl 
(PCR Product), 1 μl (1.2 M NaCl 0.6 M MgCl2), 1 μl (TOPO® vector), and 3 μl (H2O)] were 
mixed and incubated 5 min at room temperature.  The 1-2 μl of the TOPO® Cloning Reaction 
was transformed into One Shot® Competent Cells. E.coli were plated on LB-ampicillin plates [50 
μg/ml AMP (VWR, #7177-48-2)] with 160 μl of 10 μg/ml X-gal (Fisher, AB-0479) added and 
placed at 37oC overnight.  Individual colonies were selected that were white or light blue and 
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analyzed for insert by amplifying colonies in 3ml LB (50 μg/ml AMP) media overnight in a 
37oC incubator with shaking.  Plasmid DNA was purified using Wizzard® Plus SV Miniprep Kit 
(Promega) and eluted in 100 μl nuclease free H2O.  The presence of a 5S rRNA insert was 
verified by an Eco R1 digest, (the restriction site flanked both sides of the cloning site by ~10 
bp).  Electrophoresis with a 2.5% agarose gel separated the restriction fragment from the vector 
and   ~ 140 bp fragment was the ideal product. 
Big Dye Sequencing Reaction.  20 µL Sequence Reactions consisted of: 4 µL (5x 
Buffer), 3 µL (Template), 2.5 µL (2μM Primer), 1.2 µL (Big Dye V3.1 (Applied Biosystems, 
#4337455)), and 9.3 μl (H2O).  Using the following conditions: 1) 960C → 30sec, 2) 550C → 
30sec, 3) 600C → 30sec, 4) Repeat steps 1-3 (35 times), 5) 720C → 7 min final extension, 6) 40C 
→ hold.   The DNA was cleaned with magnetic beads, which bind to DNA, so excess primers 
and nucleotides can be removed as to not interfere with the sequencing signal.  Briefly, 10 µL of 
Clean Sequence (Agencourt Bioscience Corp., #009145) and 80 µL 80% ethanol were added to 
each reaction and mixed.  The mixture from each reaction was added to its own well of a skirted 
96 well plate (PGC Scientific, #62-6042-53) and placed on top of a 96 well magnet for 5 min to 
allow the beads to sufficiently bind DNA.  The beads in each well were washed twice with 200 
μl 80% ethanol then all the liquid was removed with a vacuum aspirator.  The plate was removed 
from the magnet, and 50 µl of H2O was added and mixed.  The plate was sent to a University of 
Pittsburgh sequencing facility for analysis. 
NCBI BLAST.  In order to determine exactly what gene was amplified in the 
mitochondria 28S +RT lane of figure 8, 2 μl of the PCR of the RT-reaction was used along with 
the TOPO TA Cloning® Kit to create clones with 100 bp fragment inserts (See Cloning above for 
more information).  Two clones were chosen for sequencing and upon analysis were not 100% 
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identical.  One fragment of 107 nt 28S-E named for its (position in the skirted plate) and the 
other was 28S-F contained 119 nt.  A NCBI BLASTN with parameters nr/nt was individually 
performed on each sequence.  
2.2 RESULTS 
An extensive literature search was performed to determine which 5S rRNA genes were 
expressed and if there was any information about localization of these RNAs.  The result of the 
query suggests that little information is known.  In addition, the search through Flybase revealed 
100 annotated genes of the estimated 165 were found in the 56 F region on the right arm of D.m. 
chromosome 2.  Performing a BLAST on the entire Drosophila Genome for 5S rDNAs revealed 
the 56F region plus many other less homologous single regions on other chromosomes that were 
smaller than 135bp.  Papers published more than 3 decades ago estimated the total number of 
genes to be ~200 from techniques such as 5S rRNA-DNA hybridization (Procunier and Tartof, 
1975; Procunier and Dunn, 1978).    
  Comparisons of known 120 NT 5S rDNA sequences from yeast, Drosophila, and humans 
suggested that the Drosophila sequences identified were of sufficient homology to described 5S 
rRNAs (Figure 2).  Red shaded letters represent identical sequence while white shaded lettering 
reveals variations among the species.  Next, we examined predicted secondary structures of these 
120 NS rRNAs utilizing mfold (www.bioinfo.rpi.edu/applications/mfold).  This helped us to 
determine the predicted stability of these 5S rRNA molecules and examine structural homology 
between flies and mammals.  Figure 4 depicts 5S rRNA variant III with a highly stable secondary 
structure with a ΔG of -49.9 kcal/mol.  This variant is the most prevalent isoform of the 5S genes 
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containing 48/100 of the known isoforms found in Flybase (Table 2).  We also wanted to 
determine from the literature if any other laboratory had worked on 5S rRNA transport into the 
mitochondria.  With potentially 100 copies of the gene we hoped to narrow down exactly what 
5S rRNAs were already used in experiments.  Previous data from at least three published sources  
(Yoshionari et al, 1994; Magalhaes et al, 1998; and Entelis et al, 2001) suggested that 5S rRNAs 
are imported into the mitochondria from the nucleus.    
 We performed an alignment using MegAlign software from Lasergene to categorize the 
100 genomic 5S rDNAs found in Flybase.   Based on sequence homology, 17 groups of genomic 
variants (A- Q), and 14 processed RNA counterparts (Roman Numerals: I-XIV) were established 
(Figure 3 & Table 2).  In figure 3, the red shading represent identical sequence while yellow 
lettering reveals variations among the 17 genomic groups.  Additionally, the black dotted line is 
the predicted 3’ post-transcriptional cleavage site of the 5S rRNAs fifteen NT to the left of the 
3’end (Spradling and Rubin, 1981).  Table 2, reveals the numerical breakdown of the 100 
genomic 5S rDNAs into the 14 modified post-transcriptional 120 NS RNA variants.  
With, in theory, 100 gene copies resulting in 17 genomic variants and 14 processed 5S 
rRNA counterparts and three published sources showing 5S rRNAs can be imported into the 
mitochondria from the nucleus; we needed to be able to efficiently purify the mitochondria on a 
large scale from the rest of the cytoplasm in the wild type fly.  The nucleus needed to be avoided 
because 5S rDNAs do not contain any introns and any nuclear contamination would confound 
later PCR steps.  A protocol modified from Gasnier et al, (1993), which utilized both gradient 
and percoll centrifugation steps to isolate highly purified mitochondria, was used (Figure 5).  The 
goal was to obtain mitochondria and cytosol fractions lacking any detectable contamination from 
the other fraction.  Figure 6 pictorially shows the stepwise events the purified mitochondrial and 
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cytosolic fractions underwent.  The purified fractions were re-homogenized with 6 M Urea/ 3 M 
LiCl and the RNA was extracted with Phenol (pH 4.0) /Chloroform and precipitated in NaCl and 
ethanol.  The RNA was DNase treated and then extracted again (See M&M for more details).    
Before performing the RT-PCR reaction, optimal temperature and salt conditions were 
determined using WT-gDNA template.  From preliminary PCR reactions, we learned that the 
RT-reaction would have to be placed at higher temperatures, as was the Touchdown PCR’s 
protocol optimized in order to get the appropriate products from the highly structured RNA.   
Amplifying all of the variants without introducing any bias was crucial in determining which 
variants, if any, entered the mitochondria.  A degenerate primer (5S R Deg) was made to 
determine 13 of the 14 5S rRNAs.  One 5S rRNA, variant IX, had its own reverse primer (5S R 
3371) because the last ~20 NS sequence did not correspond well with the other 13 (Figure 3).  
As noted from Figure 7, the 5S PCR product was ~120 bp.  The 16S and 28S control products 
were 170 and just over 200 bp, respectively.  These are consistent with the predicted lengths of 
122, 175, and 208 bp, respectively.  We were unable to produce an RT-PCR product using the 
reverse primer (5S R 3371) for 5S rRNA XI.  
In the PCR of the RT-reaction (+5S, +16S, +28S) the 208 bp 28S rRNA was the 
cytoplasmic control, the 175 bp 16S rRNA was the mitochondrial control and the 5SrRNAs are 
around 120 bp (Figure 6).  The nuclear control were the – RT lanes, which did not amplify 
during the RT reaction but could amplify a product if there was any nuclear/mitochondrial DNA 
present during PCR.  Figure 8 revealed 16S rRNA (mitochondrial) contamination from the 
cytoplasmic prep lanes + RT.  Importantly, there is no 28S rRNA (cytoplasmic) contamination 
from the mitochondrial PCR lanes + RT.   More significant is that the  –RT lanes for 5S rRNA 
for both cytoplasm and mitochondria were clean from contamination.  The Mito +28S lane 
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contained a 100 bp product that was the incorrect size for the 28S.  This band was cloned, 
sequenced and further analysis revealed PCR recombination from two non-contiguous pieces of 
the 28S gene.        
After we were satisfied that the mitochondrial and cytoplasmic purification protocol were 
optimized as seen from the RT and cDNA PCR, the next step was cloning and sequencing both 
mitochondrial and cytoplasmic 5S rRNAs.  For each fraction (mitochondria or cytoplasm) three 
independent TOPO® Cloning Reactions (A, B, and C) were performed using a different cDNA 
PCR sample.  Cyto (A, B, and C) and Mito (A, B, and C) were individually transformed into 
their own vial of One Shot® Competent Cells and plated individually onto LB-Ampicillin (50 
μg/ml AMP, 10 mg/ml X-GAL) plates.  Individual colonies were selected from all three plates 
that were white or light blue and analyzed for insert by amplifying colonies in 3ml LB (50 μg/ml 
AMP) media overnight in a 37oC incubator with shaking.  Plasmid DNA was purified and the 
insert was confirmed by use of the PCR 2.1 TOPO® Vector which had flanking Eco RI 
restriction sites.  When 10 μl of plasmid was cut in an Eco RI digestion ~140 bp fragment was 
created (120 bp-5S +20 bp Eco RI).  The digest was electrophoresed on a 2.5% agarose gel with 
a 100 bp marker.  White colony selection and the Eco RI digest of the insert insured there was a 
5S rDNA in the vector to sequence.   
We performed the sequencing reaction and the cleanup steps of greater than 100 positive 
clones each from the cytoplasm and mitochondria.  A sequencing primer pCRII-TOPOR was 
used to obtain insert sequence and SeqMan software program from Lasergene was used to place 
the 5S sequences into contigs based on homology.  Figure 9, the template for determining which 
variant the sequence corresponded started at base 17 and ended at base 97.  These were the first 
base after the 5S F primer and first base before the 5S R Deg respectively.  From analysis of 
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figure 9, the sequences of variants I & IV are identical between bases 17-97, so any positive 
clones from these two variants were indistinguishable.  Interestingly, the cytoplasm contained 
105 identical 5S rRNA III clones while the mitochondria consisted of 119 5S rRNA III clones.  
The mitochondria also contained 2 5S rRNA VI clones.  Our sequence analysis revealed over 100 
(+) positive 5S rRNA III clones from both the mitochondria and the cytoplasm.  Variant III was 
the predominant 5S rRNA expressed and the best vehicle to target passenger mRNAs to use in 
gene therapy.  
In conclusion, RT-PCR, PCR of the cDNA, then TOPO cloning and sequencing was used 
to determine which of the 12 5S rRNA groups are localized to the mitochondria (Note: Only 13 
of the 14 processed rRNAs could be individually determined with the primers synthesized: 
variants I & IV have NS differences only in the areas that annealed to the primer sequence so 
expression of variants I and IV are combined).  Our in vivo data are consistent with earlier in 
vitro work suggesting expressed 5S RNAs may be largely homogenous (Benhamou and Jordan, 
1975).  
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3.0  VALIDATION OF METHODIOLOGIES USED IN 2.0 
In order to validate our results that 5S rRNA III was not only the most prevalent 5S rRNA in the 
cytosol but also the most prevalent imported into the mitochondria, we had to verify that our 
assay was capable of detecting numerous variants and were unbiased.  This was our goal in using 
the degenerate 5S reverse primer, however, we needed confirmation.  We performed the same 
amplification, cloning, and sequencing procedures with the same primers and conditions only we 
used purified genomic DNA as the template.  We utilized a clonal analysis, as before, and 
hypothesized that we would now recover a mixture of 5S rDNAs clones.  
3.1 MATERIALS AND METHODS 
Preparation of CS gDNA.  A QIAamp DNA Mini Kit (QIAGEN, 51306) was used to purifying 
Genomic DNA. Vendor’s instructions were followed but modified by the Palladino Laboratory 
specifically for Drosophila.  Briefly, 10 flies were homogenized in 80 μl cold 1X PBS in a 1.5 
ml eppendorf tube.  One hundred eighty μl buffer ATL was added and mixed then 20 μl 
Proteinase K was added the solution was vortexed and placed at 56oC for 3 hrs with occasional 
vortexing.  The tube was centrifuged briefly then 4 μl of 100 mg/ml RNase A was added, 
vortexed and placed at room temperature for 2 min.  Two hundred μl buffer AL was added to the 
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tube vortexed to mix and incubated at 70 oC for 10 min.  Two hundred μl of 100% ethanol was 
added, vortexed to mix and briefly centrifuged.  The mixture was added to a QIAamp Spin 
Column and centrifuged at 8000RPM for 1 min.  Five hundred μl of AW1 wash buffer was 
added and the column was centrifuged at 8000RPM for 1 min.  Five-hundred μl of AW2 wash 
buffer was added and the column was centrifuged at 14000RPM for 3 min.  The spin column was 
placed in a clean 1.5 ml eppendorf tube 200 μl buffer AE was added and placed at RT for 2 min.  
Then the column was centrifuged at 8000RPM for 1 min. 
PCR of gDNA.  The same exact PCR Reactions and Conditions used for the 5S cDNAs 
were used for the gDNA. Three μl of purified gDNA were used in the PCR reaction. The 
forward primer was 5S F and the reverse primer was 5S R Deg in a 50 μl reaction and the same 
Hot Start-Touchdown program as before.   
 Cloning and Sequencing.  The same cloning method using the TOPO TA Cloning® Kit 
and then transforming into One Shot® Competent Cells was used on the PCR products from 
gDNA.  As before, clones with inserts were verified by loss of β-galactosidase activity and 
restriction enzyme digest and gel electrophoresis of purified plasmid DNA.  The inserts were 
sequenced and analyzed as before in 2.1 Material and Methods. 
5S rDNA-ATP6 (20 bp) Construct.  A 20 bp 5’ sequence tag of Drosophila 
melanogaster WT ATP6 mtDNA was appended by PCR onto the 120 bp 5S rDNA III (see Table 
I and Figure 10).  Briefly, PCR 2.1 TOPO® Vector plasmid DNA containing the 5S rDNA III 
insert was linearized with Age I restriction enzyme.  Two PCR reactions were run with the 
linearized vector template and primers Eco5S F (1a) & XbaAT5S R (1b) or EcoAT5S F (2a) & 
Xba5S R (2b) to create a 160 bp or larger PCR Fragment (119 bp-5S rDNA III + 20 bp ATP6 + 
10 bp Xba I + 10 bp Eco RI).  Five μl of the PCR reactions from 1a, 1aCT, 1b, and 1bCT were 
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each digested with Eco RI and Xba I at 37oC for 20 min.  The digest was electrophoresed on a 
2.5% agarose gel with a 100 bp marker and 140 bp fragment from an Eco RI digestion of the 
PCR 2.1 TOPO® Vector (120 bp-5S rDNA III +20 bp Eco RI).  One hundred fifty one bp is the 
proposed size of the digested PCR fragment (119 bp-5S rDNA III + 20 bp ATP6 + 6 bp Xba I + 
6 bp Eco RI). 
Cloning and Sequencing.  The two inserts, 1a and 1b, were cloned using the same 
method as 2.1 into the DES TOPO® Vector (pMT/V5-His TOPOV) a Drosophila Expression 
System and then transforming into One Shot® Competent Cells.  As before, clones with inserts 
were verified by loss of β-galactosidase activity and restriction enzyme digest and gel 
electrophoresis of purified plasmid DNA.  The inserts were sequenced and analyzed as before in 
2.1 Material and Methods. 
3.2 RESULTS 
The categories we used to characterize the sequences after the gDNA control was completed 
were (+) “positive sequence” and “variants not found in Flybase.”  The (+) positive sequence 
exactly matched one of the 12 5S rRNA variants between the two primers.  Variants not found in 
Flybase, were approximately 10-20% of each group’s total sequenced 5S clones.   
         By reviewing the gDNA control data from Table 3, the (+) sequences were: 37 5S rRNA I 
or VI clones, 29 5S rRNA III clones, 1 5S rRNA VII clone, and 1 5S rRNA XIV clone.  This 
genomic data is starting to mirror the expected amounts of 5S rRNAs in the 100 characterized 
from Flybase, i.e. the variants with the larger amounts of copies are starting to be represented.  
The observed lane for gDNA was calculated by [(observed = gDNA/Total#)*100].  The observed 
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was primary data, and the total # of (+) clones is 96.  This proposes if we sequenced 200-500 
more colonies the observed values would become closer to the expected gDNA values given in 
Table 3, because some of the variants with only 1 copy could become represented.  The gDNA 
clones also helped confirming that our technique was unbiased since the genomic control PCR 
was able to pick up 5 of the 12 5S rRNA variants 68/96 (+) clones or  ~71%.   
 An interesting occurrence was that 10-20% of the total 5S clones sequenced in each 
category were variants not currently established in Flybase.  While searching through the 
mitochondrial and cytoplasmic sequences, notes were taken on where and the frequency of the 
variation of the individual sequences from 5S rRNA III.  After searching through the gDNA 
controls a number of the same variations were observed.  Guidelines were set up in order to 
classify the variations based if they were found in 2 or more independent clones (i.e. the clones 
were found in 2 or more different PCR reactions) or found in 2 or more clones.  From Table 3, 
the light blue area represented the original I to XIV variants from Flybase except XI (&) which 
used a different reverse primer in the analysis.  The tan area represents variants XV to XXII 
found in 2 or more independent clones (#).  These variants were found in gDNA and cytoplasmic 
or mitochondria sequencing, a few were independent clones only from gDNA.  The last group of 
variants consisted of 2 or more clones (*) and was found in mitochondrial variants XXIII to 
XXV.   
After determining that 5S rRNA III was imported into the mitochondria, two constructs 
were made using 5S rDNA III.  Only mitochondrial clonal inserts were chosen that contained 
sequence that were identical in all 135 bp to 5S rDNA III.  By PCR, a 20 bp 5’ sequence tag of 
Drosophila melanogaster WT ATP6 mtDNA was appended onto the 120 bp 5S rDNA III (see 
Table I and Figure 10).  In figure 10, the restriction digest was electrophoresed on a 2.5% 
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agarose gel with a 100 bp marker and 140 bp fragment from an Eco RI digestion of the PCR 2.1 
TOPO® Vector (120 bp-5S rDNA III +20 bp Eco RI).  The digested PCR product was a ~ 151 bp 
Fragment (119 bp-5S rDNA III + 20 bp ATP6 + 6 bp Xba I + 6 bp Eco RI), CT1a and CT 1b did 
not contain any DNA in the PCR reaction.  In the two reverse primers (XbaAT5S R and Xba5S 
R), the last base of the 5S rDNA (A) was deleted.  This was to insure the 3’ post-transcriptional 
processing of the 135 bp genomic to 120 NS RNA would not occur and prevent deletion of the 
20 NS ATP6.  Also, since we are unsure how 5S rRNA enters into the mitochondria, we created 
the construct with the 20 bp ATP6 on either side of the 5S rDNA (Figure 10).  Whatever the 
mechanism of RNA import into the mitochondria we did not want it blocked by ATP6-mRNA 
secondary structure tagged onto the 5S rRNA. 
We characterized the 100 5S rRNAs into 14 groups or variants by sequence homology, 
and determined that 5S rRNA III was the most prevalent species in both the cytoplasm and 
mitochondria.  We will use this variant for the rest of the experiments involved in development 
of constructs for mRNA target gene therapy.  Our PCR protocol had low bias i.e., a high copy 
number in the genome lead to high frequency in clones.  Also our method amplified based on the 
amount of a certain 5S variant in the genome.  We used a genomic control to insure the number 
of 5S rDNAs were observed in the same relative pattern as in Flybase.  Our analysis provided 
good evidence that many variants are pseudogenes, as they were not found in the control or 
experimental groups.  Eight novel and 3 possible 5S genes were identified that are not currently 
categorized in Flybase.  Finally, two 5S-ATP6 constructs were cloned into DES vectors, 
sequenced and are ready for mRNA expression assays both in vivo and in vitro. 
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4.0  DISCUSSION 
Our goal was to develop a transgenic strategy where allotopic expression of a mitochondrial-
targeted ATP6 mRNA may serve as a potential gene therapy for devastating mitochondrial 
diseases.  We utilized a cluster of 100 individual 5S rRNA genes found at 56F region of the right 
arm of chromosome 2 in Drosophila melanogaster.  Sequence comparisons revealed 17 groups 
of genomic variants and 14 processed rRNAs.  A multi-centrifugation and percoll gradient 
protocol was developed to isolate highly purified mitochondria, which lacked cytosolic 
contamination.  RT-PCR, cloning, and sequencing were used to determine which 5S rRNAs were 
expressed and localized to the mitochondria.  The numerical results of the cytoplasmic, 
mitochondrial, and gDNA control clones support the assertion that, at least under normal in vivo 
conditions, ~ 60 % of the identified 5S rRNA genes are not expressed and are likely pseudogenes.  
5S rRNA III, the primary expressed variant, was localized to the mitochondria.  In addition to this 
new find, 8 novel and 3 possible 5S rRNA isoforms not presently categorized in sequence 
databases have been discovered.  Clones were generated capable of expressing chimeric 
rRNA::mRNAs in cells and in vivo (Figure 10).  These constructs could later be used to assess the 
ability of 5S rRNA to direct mitochondrial import of “passenger” mRNAs (Figure 2). 
This research required developing an assay to both purify mitochondrial RNA and 
quantify isoform expression.  Importantly, we validated our assay by performing the degenerate 
amplification and cloning protocol with purified genomic DNA, which demonstrated recovery of 
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a mixture of 5S rDNAs (Chapter 3.0).  These control data confirmed our earlier results by 
demonstrating our assay, PCR and cloning methods, were capable of detecting numerous 
variants and did not reflect a simple bias in the amplification protocol.    
Our data demonstrate that of the ~ 100 genes the cytosol is largely homogeneous with 
variant III being the major 5S rRNA present (Chapter 2.0). These data are consistent with 
previous reports (Benhamou and Jordan, 1975).  Our data also revealed the surprising finding 
that mitochondrial 5S rRNAs are also relatively homogeneous and that the major isoform present 
is variant III (Chapter 2.0).  Additionally, we identified 8 novel and 3 possible genes not 
currently categorized in Flybase and found data in support of the assertion that, at least under 
normal conditions, ~ 60 % of the identified 5S rRNA genes are not expressed and are likely 
pseudogenes (Chapter 3.0).  
The idea that over half of the identified 5S rRNA genes are likely pseudogenes becomes 
plausible when the results of the genomic control are examined.  If 100 (+) gDNA clones were 
sequenced and it was expected that all of the 5S variants were transcribed, then the observed 
total would be very close to the expected total for each variant in table 3.   However, by looking 
at the gDNA data, only 5 different variants  (I, III, IV, VI, XIV) were cloned.  Variants I & IV 
had the most copies at 37, although from our data, they never appeared in the mitochondria or 
cytoplasm.  From the 12 distinguishable 5S rRNA genes, the mitochondria contained two 
individual variants (III, VI) the most remarkable being type III while the cytoplasm only 
contained variant III.  This suggests that even if the other genes are capable of being transcribed 
the 48 copies of variant III are fully capable of the cell’s translation needs under normal 
everyday conditions.  Likewise, from our data, 5S rRNA III may be the major variant imported 
into mitochondria.  The other variants could have developed mutations over the years from DNA 
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replication or transposition in which they now differ from isoform III explaining inactivity. 
Another explanation is variant III is transcribed during stable 22oC adult conditions.  The other 
variants could be actively transcribed during embryogenesis /development, stress, or disease.  
 There are two controversies concerning 5S rRNAs presented briefly in the introduction of 
this paper.  First, if 5S rRNAs can be imported from the nucleus into the mitochondria.   Previous 
data from at least three published sources  (Yoshionari et al, 1994; Magalhaes et al, 1998; and 
Entelis et al, 2001) suggested that this is in fact what occurs.  Our data supports the 5S rRNA 
import hypothesis (Table 3).  In 2001, Entalis et al, were able to import 5S into “energized” 
(ATP was present) mitochondria with IDPs (import directing proteins) through the GIP (general 
import pore).  Using a human in vitro based assay, they found that an intact pre-protein channel, 
IDPs, and ATP were required for 5S rRNA import.  This seems like an evolutionary logical 
solution, to use a mitochondria import pathway that is already intact and functioning and adapt it 
for RNA use.  The second controversial topic concerning 5S rRNAs was whether it is a 
functional component of mitochondrial ribosomes.  The consensus from articles is that mtDNA 
of species such as plants, algae and some protozoans encode for the 5S rRNA gene and 5S rRNAs 
have been found in mitochondrial ribosomes of these species (Entelis et al, 2001).  In eukaryotes, 
including Drosophila, fungi, and mammals, the 5S genes are nuclear and some believe that 5S 
rRNAs are not incorporated into mitochondrial ribosomes of these species (Entelis et al, 2001). 
One hypothesis is that Leishmania tarentolae, Chlorokybus atmophyticus and Coffea arabica 
have larger genomes in general (20,992 nt, 201,763 nt, and 155,189 nt), while most species 
including: Drosophila melanogaster, Neurospora crasse, and Homo sapiens have smaller and 
more compact genomes (19,517 nt, 7,050 nt, and 16,571 nt). 
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Future directions for this project include determining the utility of 5S rRNA III as a 
vehicle to target passenger RNAs suggesting a viable gene therapy approach.  By PCR, we 
appended a 20 bp 5’ sequence tag of ATP6, onto the 120 bp 5S rDNA III (see Table I and Figure 
10).  Eco RI and Xba I were constructed in the primers to create restriction sites in order to place 
the construct into expression vectors, namely pUAST and “DES TOPO” (pMT/V5-His TOPOV) 
a Drosophila Expression System.  With more evidence pointing toward a RNA import pathway, 
our vector constructs could be transfected into Drosophila S2 cells and the localization of the 
ATP6::5SRNA chimera into the mitochondria determined by RT-PCR. 
In conclusion, we characterized ~100 5S rRNAs into 14 groups or variants by sequence 
homology and determined that variant III was the most prevalent species in Drosophila 
mitochondria.  This suggests that variant III may serve as a viable carrier of “passenger” 
 mRNA that may be of therapeutic value.  We aim to use the 5S rRNAs to target 5S::ATP6 
mRNA into mitochondria and assess the ability of allotopic mRNA expression to rescue the 
mtATP61 mitochondrial mutation in vivo.  We will generate transgenic flies expressing the 
chimeric 5S::ATP6 mRNA.  The long-term goal is to elucidate details of mitochondrial RNA 
import and determine the feasibility of exploiting this function as an avenue of gene therapy for 
mitochondrial disease.   
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 APPENDIX-A   FIGURES    
Figure 1.   Proposed 5S rRNA Import Pathway 
 
Figure 1 depicts a RNA Import Pathway where 5S rRNA transcribed in the nucleus can be 
imported into the mitochondria.  For mRNA allotopic expression gene therapy, the gene would 
encode a fusion 5SrRNA::mRNA.  The 5S rRNA is a transporter that would be recognized by the 
RNA import pathway and the mRNA is a WT gene (D.m. ATP6) referred to as a passenger RNA. 
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Figure 2.   5S rRNA Homology Between Species  
 
 
 
Figure 2 represents a comparison of known 120 NT 5S rDNA sequences from yeast, Drosophila 
and humans, ensuring that the known Drosophila sequences (D.m.5SJ01122, D.m.5SX87880, 
and D.m.5SM25016) showed sufficient homology to described 5S rRNAs.  Red shaded letters 
represent identical sequence while white shaded lettering reveals variations among the species. 
S.c. is the yeast Saccharomyces cerevisiae and S.p. is yeast Sichizosaccharomyces pombe, D.m. 
is Drosophila melanogaster and H.s. is Homo sapiens. 
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Figure 3. 17 Genomic Variants of 5S rDNA  
 
 
 
Figure 3 represents 17 groups of 5S rDNA genomic variants (A- Q).  The red shading represent 
identical sequence while yellow lettering reveals variations among the 17 genomic groups.  The 
black dotted line is the predicted 3’ post-transcriptional cleavage site of the 5S rRNAs  (the 14 
processed RNA counterparts are Roman Numerals: I-XIV found in Table 2). 
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 Figure 4. Secondary Structure of 5S rRNA III 
 
ΔG= -49.9 kcal/mol
Figure 4 depicts 5S rRNA variant III with a highly stable secondary structure with a ΔG of -49.9 
kcal/mol.  This variant is the most prevalent isoform of the 5S genes containing 48/100 of the 
known copies found in Flybase (Table 2).  Our findings also indicate it was the most common 
variant found in the D.m. cytoplasm and mitochondria (see Table 3). 
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 Figure 5.  Purification of Mitochondria and Cytoplasm 
 
In figure 5, a protocol modified from Gasnier et al, (1993), which utilized both gradient and 
percoll centrifugation steps to isolate highly purified mitochondria, was used.  The goal was to 
obtain mitochondria and cytosol fractions lacking any detectable contamination from the other 
fraction. 
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Figure 6.  Scheme for RNA Purification and 5S rRNA Determination 
1. Separate RNA from Mito
or Cyto Fractions
     - Homogenize with 6 MUrea/3 MLiCl
         - Extract with Phenol/Chloroform (pH
4.0)
         - Precipitate with NaCl & Ethanol
         - DNase treat Precipitate
         
 
Figure 6 describes the stepwise events the purified mitochondrial and cytosolic fractions 
underwent.  1.) The purified fractions were re-homogenized with 6 M Urea/ 3 M LiCl and the 
RNA was extracted with Phenol (pH 4.0) /Chloroform and precipitated in NaCl and ethanol.  
The RNA was DNase treated and then extracted again (See M&M for more details).  2.) 
Pictorially depicts the Reverse Transcriptase reaction using RNA and a RT primer resulting in 
cDNA.  3.) Pictorially describes the PCR reaction using cDNA as a template and resulting in 
double stranded 5S rDNA.  4.) Describes the controls of the RT /PCR reactions. 
 
 
* Whole RNA (rRNA, mRNA, tRNA)
2. Reverse Transcriptase
3.   PCR of cDNA
RT Primer
cDNA: RNA/ DNA Hybrid
RNA
DNA
RNA
RNA
DNA
DNA
RNA
5S R Deg Primer
5S F Primer
DNA
DNA
120 bp 5SrDNA
4.   RT Plus Controls
-+28S rRNA
+-16S rRNA
++5S rRNA
MitochondriaCytoplasm
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Figure 7.  PCR to Check Primers and System Conditions 
 
100
200
Deg 3371 16S 28S
Clone
# 19
208
175
122
5S5S100bp
Marker
300
In figure 7, 20 μl was electrophoresed on a 2.5% agarose gel with a 100 bp marker.  The 5S PCR 
product was around 120 bp, the 16S 170 bp and the 28S just over 200 bp, which corresponds to 
the predicted lengths of 122, 175, and 208 bp, respectively.  We were unable to produce a 
product from the reverse primer (5S R 3371) for 5S rRNA XI.  
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Figure 8.  PCR of cDNA                                                                              
In figure 8, 20 μl was electrophoresed on a 2.5% agarose gel with a 100 bp marker.   The 208 bp 
28S rRNA was the cytoplasmic control, the 175 bp 16 SrRNA was the mitochondrial control and 
5S rRNAs are around 120 bp.  There is 16 SrRNA (mitochondrial) contamination from the 
cytoplasmic prep lanes + RT.  Importantly, there is no 28S rRNA (cytoplasmic) contamination 
from the mitochondrial PCR lanes + RT.  More significant is that the  –RT lanes for 5S rRNA for 
both cytoplasm and mitochondria were clean from contamination.  The Mito +28S lane 
contained a 100 bp product that was the incorrect size for the 28S.  This band was cloned, and 
sequenced and further analysis revealed PCR recombination from two non-contiguous pieces of 
the 28S gene.       
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Figure 9.   5S rDNA Sequence Templates (-) Minus Primers 
 
 
Figure 9 is the template for determining which variant the sequenced clone corresponded.  The 
template started at base 17 and ended at base 97, these were the first base after the 5S F primer 
and first base before the 5S R Deg respectively.  In this template 5S rRNA I & IV were identical 
when the primer sequences were removed. 
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  Figure 10.  Constructs using 5S rDNA III 
1.  Add the first 20 bp of ATP6 to 5SrRNA
  5SrRNA ATP6EcoR1 Xba1   5SrRNAATP6EcoR1 Xba1
2.  Perform 2 PCR reactions then check  results by agarose gel
      electrophoresis of the  Eco  RI and Xba I digest
a b
1a 1b140bp 1a CT 1b CT
100bp
200bp ~150 bp product
Eco5S F EcoAT5S F
Xba5S RXbaAT5S R
100 bp
Marker
 
In figure 10, 5 μl digest was electrophoresed on a 2.5% agarose gel with a 100 bp marker and 
140 bp fragment from an Eco RI digestion of the PCR 2.1 TOPO® Vector (120 bp-5S rDNA III 
+20 bp Eco RI).  The PCR product was ~ 151 bp fragment (119 bp-5S rDNA III + 20 bp ATP6 + 
6 bp Xba I + 6 bp Eco RI), and the PCR reactions for 1a CT and 1b CT did not contain any 
DNA. 
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APPENDIX-B  TABLES 
  Table 1.  List of Primers and their Sequences 
 
Primer Sequence  
  
5S F 5'- GCC AAC GAC CAT ACC A -3' 
5S R Deg 5'- AGK CCA AYA RCA CRC GGT GTT CC -3' 
5S  R 3371  5'- AGG CCA ACT ACC GAT TCA GTA ATC -3' 
16S F 5'- GTT ACT TTA GGG ATA ACA GCG -3' 
16S R 5'- AAC CAA CCT GGC TTA CAC CGG -3' 
16S RT 5'- TTT GAT ATT TGG TCC TTT CGT AC -3' 
28S F 5'- CAG GTT GAA GTC AGG CGA AAC C -3' 
28S R 5'- GAC CCT AAG GCC TCT AAT CAT TCG C -3' 
28S RT 5'- CCA TTT AAA GTT TGA GAA TAG GTT AAG -3' 
 PCRII-TOPO R 5'- GCC CAA TAC GCA AAC CG -3' 
Eco5S F (1a) 5'- ACT GCG AAT TCG CCA ACG ACC ATA CCA CGC T -3' 
EcoAT5S F (2a) 5'- ACT GCG AAT TCA TGA TAA CAA ATT TAT TTT CGC CAA CGA CCA TAC CAC GCT -3' 
Xba5S R (2b) 5'- ACA AGT CTA GAG GCC AAC AAC ACG CGG TGT T -3' 
XbaAT5S R (1b) 5'- ACA AGT CTA GAG AAA ATA AAT TTG TTA TCA TGG CCA ACA ACA CGC GGT GTT -3' 
 
In table 1, are the names of the primers and their sequences used in this Thesis.  The bold letters 
in the sequences stand for the ATG =AUG start codons for the Drosophila WT ATP6 mRNA 
constructs. 
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Table 2.  Drosophila Melanogaster 5S rRNA Sequences 
 
Genomic Variants  rRNA Variants 
        
Group # Group # 
        
A 22     
B 2     
C 1 I 25 
D 2     
E 1 II 3 
F 48 III 48 
G 5 IV 5 
H 3 V 3 
I 7 VI 7 
J 2 VII 2 
K 1 VIII 1 
L 1 IX 1 
M 1 X 1 
N 1 XI 1 
O 1 XII 1 
P 1 XIII 1 
Q 1 XIV 1 
        
Total 100 Total 100 
        
 
In table 2, based on sequence homology, 17 groups of genomic variants (A- Q), and 14 
processed RNAs (Roman Numerals: I-XIV) were established.  The numerical breakdown of the 
100 genomic 5S rDNAs into the 14 modified post-transcriptional 120 NS RNA variants is also 
shown. 
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Table 3.  Results of 5S rRNA Localization with Novel Variant Determination 
5S rRNA Cytoplasmic Mitochondrial gDNA  
Expected 
gDNA 
Observed 
gDNA 
            
#I or IV 0 0 37 25+5=30 38.5 
II 0 0 0 3 0.0 
#III 105 119 29 48 30.2 
V 0 0 0 3 0.0 
#VI 0 2 1 7 1.0 
VII 0 0 1 2 1.0 
VIII 0 0 0 1 0.0 
IX 0 0 0 1 0.0 
X 0 0 0 1 0.0 
&XI 0 0 0 1 0.0 
XII 0 0 0 1 0.0 
XIII 0 0 0 1 0.0 
XIV 0 0 1 1 1.0 
#XV 0 4 2 0 2.1 
#XVI 0 0 4 0 4.2 
#XVII 0 2 2 0 2.1 
#XVIII 0 0 5 0 5.2 
#IXX 0 0 3 0 3.1 
#XX 1 1 1 0 1.0 
#XXI 0 0 4 0 4.2 
#XXII 0 0 2 0 2.1 
*XXIII 0 3 0 0 0.0 
*XXIV 0 2 0 0 0.0 
*XXV 0 2 0 0 0.0 
 
In table 3, the light blue represented the original I to XIV variants from Flybase except XI (&) 
which used a different reverse primer in the analysis.  The tan area represents variants are XV to 
XXII found in 2 or more independent clones (i.e. independent PCRs) (#).  Normally the variants 
were found in both gDNA and the cytoplasmic or mitochondria sequencing, a few were 
independent clones only from the gDNA.  The last group of variants consisted of 2 or more 
clones (*) and was found in the mitochondrial variants XXIII to XXV.  
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